In the Margins

Valeant names hedge fund partner to board

October 26, 2015

By Forbes

Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes

 

 

Most Read

Top of the Agenda - Governance
Victory-USAA deal: New board leadership on deck

In an unusual move, the board overseeing USAA's mutual funds is planning to replace its long-serving independent chairman with an interested chair upon completion of Victory ...

Viewpoints
Government shutdown hits funds, fund boards

Many news reports have recounted how the partial government shutdown has affected government employees, shuttered national parks, and unsettled the stock market. But few, if any, ...